ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today that it has secured an additional $20 million
AI market intelligence platform AlphaSense snags strategic investment from EDBI
THE investing arm of the Economic Development Board of Singapore, EDBI, has made an undisclosed strategic investment into artificial intelligence (AI) market intelligence platform
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
Notice: Unauthorised use of the EDBI name and branding in Japan. EDBI officers will never solicit from the public or offer incentives for participation in our programmes. Report any incident to [email protected] if you are unsure if something is a scam.
We may use cookies and similar technologies as necessary to run the website and offer you the best possible user experience. By clicking on "Accept", you consent to the use of all cookies and similar technologies as described in our Privacy Policy.